Anti-SARS-CoV-1, Spike (Clone COV1-80) – Purified No Carrier Protein

Sequenced from PBMCs from a donor who had recovered from a naturally-occurring SARS infection.

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

COV1-80 targets the prefusion spike protein of SARS-CoV-1 and SARS-CoV-2.

SARS-CoV-1, also known as the Severe Acute Respiratory Syndrome coronavirus, is a zoonotic virus that is believed to have originated from an animal reservoir, possibly horseshoe bats, and transmitted to humans¹. This virus primarily affects the respiratory system and can cause symptoms such as muscle pain, headache, fever, cough, dyspnea, and pneumonia^1,2. It was the first severe and readily transmissible new disease to emerge in the 21st century, with the capacity to spread globally via international air travel.

The COV1-80 monoclonal antibody is cross-reactive, targeting the spike protein of both SARS-CoV-1 and SARS-CoV-2. While it does not block the ACE2 receptor, COV1-80 still functions as a neutralizing antibody, meaning it can inhibit the virus's capacity to infect host cells. The exact epitope that COV1-80 binds to remains unidentified, highlighting the need for further research to understand its mechanism of action fully. Nonetheless, the demonstrated neutralizing activity of COV1-80 makes it a promising candidate for therapeutic strategies, particularly in combination therapies that target multiple viral epitopes for enhanced effectiveness.

Anti-SARS-CoV-1 recognizes antigens on infected cells, including respiratory epithelial cells.

1. Mann R, Perisetti A, Gajendran M, Gandhi Z, Umapathy C, Goyal H. Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks. Front Med (Lausanne). 2020;7:581521.
2. Rat P, Olivier E, Dutot M. SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential. Eur Rev Med Pharmacol Sci. 2020;24(14):7880-7885.